论文部分内容阅读
目的探讨活体亲属肾移植的临床应用价值。方法回顾性分析我院2002年2月～2006年5月完成的19例活体亲属肾移植的临床效果。结果19例供者术中均未输血,术后未发生严重的并发症,于术后7～10天出院。术后随访1～51个月,平均28个月,复查肝、肾功能均正常。19例受者术后随访1～51个月,平均28个月,其中16例术后3～5天肾功能恢复正常,3例于术后3周内肾功能恢复正常。2例发生急性排斥反应,其中1例经激素冲击治疗后逆转,另1例激素治疗无效,改用抗人血淋巴细胞球蛋白治疗10天后逆转。1例为同卵双生兄弟之间肾移植,术后仅用激素治疗3周,未用其他免疫抑制剂,未发生急性排斥反应。2例术后情况良好,半年后自行减量乃至停用免疫抑制剂,导致急性排斥反应,经激素冲击治疗后好转。1年人/肾存活率为100%。结论活体亲属肾移植安全可行;受者人/肾存活率高。
Objective To investigate the clinical value of living relative renal transplantation. Methods A retrospective analysis of our hospital from February 2002 to May 2006 completed 19 cases of living relatives kidney transplantation clinical effect. Results All the 19 donors had no intraoperative blood transfusion, no serious complications occurred and were discharged from 7 to 10 days after operation. The patients were followed up for 1 ~ 51 months with an average of 28 months. The liver and kidney functions were all normal. Nineteen patients were followed up for 1 ~ 51 months, an average of 28 months, of which 16 cases returned to normal after 3 to 5 days of renal function, and 3 cases returned to normal within 3 weeks after operation. 2 cases of acute rejection occurred, including 1 case of reversal after hormone shock therapy, the other 1 case of hormone therapy is invalid, switch to anti-human blood lymphocyte globulin after 10 days of treatment reversed. 1 case of identical twins with renal transplantation, postoperative hormone therapy for only 3 weeks, no other immunosuppressive agents, no acute rejection. 2 cases were in good condition after operation. After six months, they reduced or even stopped immunosuppressive agents, resulting in acute rejection and improvement after hormone shock treatment. 1 year human / kidney survival rate of 100%. Conclusion Living relatives kidney transplantation is safe and feasible; the recipient / kidney survival rate is high.